|
|
|
|
|
Legal status
Patent revoked (after opposition at EPO)
| (51) | INT.CL. | A61K 38/26 | (2006.01) |
| A61K 9/00 | (2006.01) | ||
| A61P 3/10 | (2006.01) | ||
| A61P 3/04 | (2006.01) |
| (11) | Number of the document | 2347762 |
| (13) | Kind of document | T |
| (96) | European patent application number | 10016112.4 |
| Date of filing the European patent application | 2006-08-18 | |
| (97) | Date of publication of the European application | 2011-07-27 |
| (45) | Date of publication and mention of the grant of the patent | 2019-05-08 |
| (46) | Date of publication of the claims translation | 2019-08-26 |
| (30) | Number | Date | Country code |
| 709604 P | 2005-08-19 | US | |
| 779216 P | 2006-03-03 | US |
| (72) |
Fineman, Mark, US
Macconell, Leigh, US
Taylor, Kristin, US
|
| (73) |
Amylin Pharmaceuticals, LLC,
9360 Towne Centre Drive, San Diego, CA 92121,
US
AstraZeneca Pharmaceuticals LP, 1800 Concord Pike, Wilmington, DE, US |
| (74) |
Jurga PETNIŪNAITĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (54) | Eksendinas, skirtas diabeto gydymui ir kūno svorio mažinimui |
| EXENDIN FOR TREATING DIABETES AND REDUCING BODY WEIGHT |
| Payment date | Validity (years) | Amount | |
| 2023-08-04 | 18 | 347.00 EUR |
| Patent revoked (after opposition at EPO) | ||
| Invalidation date | 2023-12-07 |